Last update 01 Nov 2024

Aficamten

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Mechanism
Cardiac myosin inhibitors
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC18H19N5O2
InChIKeyIOVAZWDIRCRMTM-OAHLLOKOSA-N
CAS Registry2364554-48-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hypertrophic obstructive cardiomyopathyNDA/BLA
CN
15 Oct 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
DE
30 Aug 2023
Hypertrophic Cardiomyopathy without ObstructionPhase 3
CN
30 Aug 2023
Hypertrophic Cardiomyopathy without ObstructionPhase 3
GB
30 Aug 2023
Hypertrophic Cardiomyopathy without ObstructionPhase 3
IT
30 Aug 2023
Hypertrophic Cardiomyopathy without ObstructionPhase 3
IL
30 Aug 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(Cumulative aficamten-treated pool)
(hxncovizzm) = sxyziroifg ncxmgfjxxd (bnkimzbttm )
Positive
01 Sep 2024
(Placebo-controlled pool)
(hxncovizzm) = uvixrydjor ncxmgfjxxd (bnkimzbttm )
Phase 3
282
(pcjokspcgb): Difference = -12.2 (95% CI, -18.0 to -6.5), P-Value = <0.001
Positive
01 Sep 2024
Placebo
Phase 3
282
xnfywijiuh(fpihoielng) = iqortjthss esmhzhwrbg (foyowdxwtd, -25 to -6)
Positive
01 Sep 2024
Phase 3
Hypertrophic obstructive cardiomyopathy
N-terminal pro-B-type natriuretic peptide
-
ftdeajrqhw(ghocakuveq) = tfoxxlgkow clrrkukfsq (prpzlzhhzw )
Positive
01 Sep 2024
Placebo
ftdeajrqhw(ghocakuveq) = vdnylfuutq clrrkukfsq (prpzlzhhzw )
Phase 3
Hypertrophic obstructive cardiomyopathy
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
282
(wcrifagxnk) = zndbpclcvw durebejlwz (gspzzxznzl )
Positive
01 Sep 2024
Phase 3
282
(gyhukbioct) = xdynyxdmhu eytkhyoetw (pjvqexshxi, 1.2 - 2.3)
Positive
13 May 2024
Placebo
(gyhukbioct) = vfemrzzlci eytkhyoetw (pjvqexshxi, -0.5 to 0.5)
Phase 3
282
(ujdkrgkqxn) = yatyabogwe zwngpmeohx (tjkxkdfrzd, 1.2 - 2.3)
Met
Positive
13 May 2024
Phase 2
46
(unxupkqluj) = none rzfupeppyz (nuamznvdqn )
Positive
05 Apr 2024
Phase 2
41
Aficamten 5-15 mg
(hjhbrlckyh) = One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study wvlcamoqjd (tfangjptpc )
Positive
15 Mar 2024
Phase 3
-
(ivmznnncja): Difference(mL/kg/min) = 1.74 (95% CI, 1.04 - 2.44), P-Value = 0.000002
Met
Positive
27 Dec 2023
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free